NKTR

Nektar Therapeutics' stock (NKTR) has experienced significant volatility, declining by 29.55% over the past year and 43.74% in the past month, with a share price of $42.22 as of October 5, 2026. Key events include a successful $460 million public offering in February 2026, strengthening its financial position. The Q2 2026 earnings report in August 2026 showed a smaller-than-expected loss but slightly missed revenue forecasts. In October 2026, Nektar was downgraded by some analysts due to safety concerns with REZPEG, specifically a high rate of injection site reactions (91.7%) in the REZOLVE-AA study, despite positive efficacy. Nektar was also awarded $90 million in a jury verdict against Eli Lilly for breach of contract. As of October 9, 2026, the stock has a consensus rating of 'Moderate Buy' with an average target price of $138.50.